Lipella Pharmaceuticals Inc. (LIPO) — 8-K Filings

8-K Filings (33)

• Lipella Pharmaceuticals Announces Board and Officer Changes — Oct 21, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on October 20, 2025, changes in its board of directors and executive officers. The filing details the departure of certai
• Lipella Pharmaceuticals Inc. Announces Board and Executive Changes — Oct 9, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on October 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected Dr. J
• 8-K Filing — Sep 18, 2025
• Lipella Pharmaceuticals Files 8-K — Jun 25, 2025 Risk: low
  Lipella Pharmaceuticals Inc. filed an 8-K on June 25, 2025, reporting on other events and financial statements. The filing does not contain specific financial f
• Lipella Pharmaceuticals Faces Delisting Concerns — Jun 20, 2025 Risk: high
  Lipella Pharmaceuticals Inc. filed an 8-K on June 20, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also incl
• Lipella Pharmaceuticals Files 8-K — Jun 16, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on June 16, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event, dollar amo
• Lipella Pharmaceuticals Faces Delisting Concerns — May 16, 2025 Risk: high
  Lipella Pharmaceuticals Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's princip
• Lipella Pharmaceuticals Files 8-K — May 15, 2025 Risk: low
  Lipella Pharmaceuticals Inc. filed an 8-K on May 15, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Oth
• Lipella Pharmaceuticals to Acquire Immuno-Oncology Therapeutics — Apr 14, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on April 14, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Immuno-Oncology T
• Lipella Pharmaceuticals Files 8-K on Corporate Changes — Apr 9, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on April 9, 2025, reporting material modifications to security holder rights and amendments to its articles of incorpo
• Lipella Pharmaceuticals Enters Material Definitive Agreement — Apr 7, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on April 7, 2025, that it entered into a material definitive agreement on April 4, 2025. The filing also includes financi
• Lipella Pharmaceuticals Files 8-K with Material Agreement — Mar 18, 2025 Risk: medium
  On March 12, 2025, Lipella Pharmaceuticals Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The c
• Lipella Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Mar 11, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on March 11, 2025, that it entered into a material definitive agreement on March 5, 2025. The company also reported on un
• Lipella Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Mar 3, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. announced on March 3, 2025, that it entered into a material definitive agreement on February 25, 2025. The company also reported on
• Lipella Pharmaceuticals Files 8-K for Material Agreement — Feb 24, 2025 Risk: medium
  On February 24, 2025, Lipella Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The filing was made o
• Lipella Pharmaceuticals Files 8-K — Feb 11, 2025 Risk: low
  Lipella Pharmaceuticals Inc. filed an 8-K on February 11, 2025, reporting on its status as a registrant. The company's common stock trades on The Nasdaq Stock M
• Lipella Pharmaceuticals Faces Delisting Concerns — Jan 13, 2025 Risk: high
  Lipella Pharmaceuticals Inc. filed an 8-K on January 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's pri
• Lipella Pharmaceuticals Files 8-K on Agreements and Equity Sales — Jan 6, 2025 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on January 6, 2025, reporting on events as of December 31, 2024. The filing indicates an entry into a material definit
• Lipella Pharmaceuticals Files 8-K: Agreements & Shareholder Rights — Dec 30, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. announced on December 30, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sal
• Lipella Pharmaceuticals Files 8-K — Dec 27, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on December 27, 2024, reporting other events. The company, incorporated in Delaware, has its principal executive offic
• Lipella Pharmaceuticals to Acquire Bio-Innovations, LLC — Dec 20, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. announced on December 20, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests
• Lipella Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Dec 10, 2024 Risk: medium
  On December 5, 2024, Lipella Pharmaceuticals Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The
• Lipella Pharmaceuticals Files 8-K — Dec 6, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on December 6, 2024, to report other events. The filing does not contain specific details about the nature of these ev
• Lipella Pharmaceuticals Files 8-K on Rights and Bylaws — Nov 7, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on November 7, 2024, reporting material modifications to the rights of security holders and amendments to its articles
• Lipella Pharmaceuticals Files 8-K — Nov 1, 2024 Risk: low
  Lipella Pharmaceuticals Inc. filed an 8-K on November 1, 2024, reporting other events and financial statements. The filing does not contain specific financial f
• Lipella Pharmaceuticals Faces Nasdaq Delisting Warning — Oct 18, 2024 Risk: high
  Lipella Pharmaceuticals Inc. received a notice on October 18, 2024, indicating it failed to meet the continued listing standards for The Nasdaq Capital Market.
• Lipella Pharmaceuticals Inc. Files 8-K on Shareholder Vote — Sep 11, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. filed an 8-K on September 11, 2024, reporting on matters submitted to a vote of security holders on September 10, 2024. The filing
• Lipella Pharmaceuticals Faces Delisting Concerns — Aug 23, 2024 Risk: high
  Lipella Pharmaceuticals Inc. filed an 8-K on August 23, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The ea
• Lipella Pharmaceuticals to Acquire Bio-Gen Innovations for $1M — Aug 6, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. announced on August 6, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of
• Lipella Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Aug 1, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. announced on August 1, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
• Lipella Pharmaceuticals Faces Delisting Concerns — Apr 19, 2024 Risk: high
  Lipella Pharmaceuticals Inc. filed an 8-K on April 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event
• Lipella Pharmaceuticals Changes Fiscal Year End — Apr 12, 2024 Risk: low
  Lipella Pharmaceuticals Inc. filed an 8-K on April 12, 2024, reporting a change in its fiscal year end to December 31st. This filing also includes financial sta
• Lipella Pharmaceuticals Enters Material Definitive Agreement — Mar 15, 2024 Risk: medium
  Lipella Pharmaceuticals Inc. announced on March 15, 2024, that it entered into a material definitive agreement on March 13, 2024. The filing does not disclose s

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX